SAVA
Filana Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.32
+2.33%Oct 28, 2026, 12:00 UTC
FILANA THERAPEUTICS, INC. announced publication in the journal Cells of Yale researchers’ preclinical study of simufilam in a TSC2-deficient human cell line.
Source:Oct 1, 2026, 12:01 UTC
Filana Therapeutics director, president and CEO Richard Barry bought 306,813 shares of the company for $278,132, per a Form 4 filed with the SEC.
Source:Sep 22, 2026, 12:00 UTC
The U.S. Food and Drug Administration lifted the clinical hold on Filana Therapeutics' investigational new drug application for simufilam, enabling a planned Phase 2a study in patients aged 12 to 55 with TSC-related epilepsy.
Sep 18, 2026, 20:17 UTC
Filana Therapeutics, Inc. received a Nasdaq notice dated September 17, 2026 that it no longer complies with the minimum bid price requirement under Listing Rule 5550(a)(2), giving it until March 16, 2027 to regain compliance.
Jul 29, 2026, 12:00 UTC
Filana Therapeutics reported financial results for the second quarter ended June 30, 2026.
Source:Jun 15, 2026, 00:00 UTC
Filana Therapeutics, Inc. elected Richard J. Barry, Pierre Gravier, and Claude Nicaise as directors effective June 11, 2026.